SCHEMBL14349688

SCHEMBL14349688

Cc1ccc2c(ccc3[nH]ncc32)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.42
ITK Q08881 3/20 0.42
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
LMNA P02545 2/20 0.42
HSD17B10 Q99714 2/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
METAP2 P50579 1/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2A6 P11509 2/20 0.41
ACHE P22303 1/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
MAPT P10636 4/20 0.40
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
MAP2K4 P45985 2/20 0.40
HCAR2 Q8TDS4 1/20 0.39
MAPK1 P28482 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12872 0.79 ROCK2 (0.59) IDO1ALDH1A1KDM4EHPGDGAA
SCHEMBL29409358 0.79 ROCK2 (0.59) IDO1ALDH1A1KDM4EHPGDGAA
SCHEMBL12123553 0.78 DHPS (0.43) ITKMETAP2HCAR2
SCHEMBL12125845 0.78 HCAR2 (0.47) IDO1ALDH1A1KDM4ELMNAHPGD
SCHEMBL4548305 0.78 METAP2 (0.46) IDO1ALDH1A1KDM4EHPGDGAA
Bromide SCHEMBL17924434 0.77 ROCK2 (0.57) IDO1ALDH1A1KDM4EHPGDGAA
SCHEMBL12321248 0.76 NOS1 (0.56) IDO1ALDH1A1KDM4EHPGDGAA
SCHEMBL607927 0.76 CYP1A2 (0.71) ALDH1A1KDM4ELMNAHSD17B10HPGD
SCHEMBL12354 0.75 KDM4E (0.59) IDO1ALDH1A1KDM4ELMNAHSD17B10
SCHEMBL20060303 0.75 KDM4E (0.59) IDO1ALDH1A1KDM4ELMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2865381-A1 ITK inhibitors for treating blood cell malignancies Pharmacyclics, Inc. (US) 2015-04-29 EP disclosed
US-20140080833-A1 INTRACELLULAR KINASE INHIBITORS MANNKIND CORPORATION (US) 2014-03-20 US disclosed
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-27 US disclosed
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299101-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment LDLR, APOB, FFAR1 IDO1 2842/4885ITK 3865/4885ALDH1A1 1614/4885
US-20140080833-A1 INTRACELLULAR KINASE INHIBITORS PI4KB, BTK, LTK IDO1 1130/4885ITK 79/4885ALDH1A1 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.